CliffBio
small molecule

PYRIDOSTIGMINE BROMIDE

PYRIDOSTIGMINE BROMIDE

Loss of exclusivity—loss of exclusivity
CompanyNovitium Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand namePYRIDOSTIGMINE BROMIDE
Active ingredientPYRIDOSTIGMINE BROMIDE
Strength60MG/5ML
Dosage formSYRUP
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2019
Marketing statusRX

More from Novitium Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.